Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 8% – Time to Sell?

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were down 8% during mid-day trading on Thursday . The company traded as low as $21.79 and last traded at $21.86. Approximately 2,687,463 shares changed hands during mid-day trading, a decline of 8% from the average daily volume of 2,915,662 shares. The stock had previously closed at $23.77.

Key Stories Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Company press release & webcast: Sarepta presented the initial Phase 1/2 results showing muscle exposure, biomarker activity and favorable tolerability for SRP‑1001 and SRP‑1003 — the catalyst for the sharp rally as investors price in potential new rare‑disease franchises. Business Wire: Sarepta Announces First Clinical Data
• Positive Sentiment: Market reaction & analyst upside: Media and research notes highlighted the data as meaningful proof‑of‑concept for muscle delivery, driving heavy volume, option buying and multi‑day share gains; some outlets and analysts raised upside forecasts. Zacks: SRPT Soars
• Positive Sentiment: Broker upgrades / price‑target hikes from some firms (e.g., Morgan Stanley coverage mentioned by market outlets) amplified bullish sentiment and likely supported the spike. InsiderMonkey: Morgan Stanley PT Hike
• Positive Sentiment: Elevated options and volume: Unusually large call buying and above‑average trading volume indicate speculative / speculative‑to‑directional positioning that can amplify moves on news. (No article link)
• Neutral Sentiment: Valuation/expectations story: Several analyses caution that the stock’s rebound complicates valuation — analysts note big upside if programs progress, but emphasize early‑stage risk and thin long‑term revenue visibility. Yahoo Finance: Valuation After siRNA Results
• Neutral Sentiment: Conference call / transcript coverage available — useful for digging into biomarker magnitude, safety details and next steps, but does not yet resolve clinical or commercial risk. Seeking Alpha: Transcript
• Negative Sentiment: Analyst skepticism and cautionary takes: Some analysts and commentators say it’s “too early to get excited” — warning that small early cohorts, surrogate biomarker signals and uncertain clinical benefit require more data before re‑rating the company. Seeking Alpha: Too Early To Get Excited
• Negative Sentiment: Mixed analyst actions: Citigroup raised its price target modestly to $13 but kept a sell rating (signals downside vs. rally levels), and Needham reaffirmed an underperform/negative view — these keep short‑to‑medium‑term selling pressure possible if follow‑up data or guidance disappoints. Benzinga: Analyst Notes

Wall Street Analysts Forecast Growth

SRPT has been the topic of a number of recent research reports. Loop Capital set a $25.00 price objective on Sarepta Therapeutics in a research note on Tuesday, March 3rd. Wall Street Zen raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings reiterated a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. Wedbush lowered their price target on shares of Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Finally, Royal Bank Of Canada upped their price objective on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a report on Thursday, January 8th. Nine analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $32.30.

Sarepta Therapeutics Stock Down 9.2%

The firm has a 50-day moving average of $18.70 and a two-hundred day moving average of $19.96. The company has a market capitalization of $2.27 billion, a PE ratio of -2.55, a price-to-earnings-growth ratio of 0.28 and a beta of 0.42. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). The business had revenue of $442.93 million for the quarter, compared to analysts’ expectations of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The business’s revenue for the quarter was down 32.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.90 earnings per share. Equities research analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the transaction, the director owned 1,765 shares of the company’s stock, valued at $30,040.30. This trade represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC purchased a new position in shares of Sarepta Therapeutics during the 4th quarter worth approximately $25,000. iSAM Funds UK Ltd purchased a new stake in Sarepta Therapeutics in the third quarter valued at approximately $25,000. Ancora Advisors LLC lifted its stake in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares in the last quarter. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics during the third quarter worth $33,000. Finally, Allworth Financial LP boosted its position in shares of Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,721 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.